ATP2B2 and neoplasm: On the background of PMCA2 deficiency, we found that a low dose of doxorubicin was sufficient for pronounced inhibition of MDA-MB-231 proliferation in vitro, suggesting tumor-targeted PMCA2 depletion or inhibition may allow the use of doxorubicin doses associated with a better side effect profile in these cells.